Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice

Pathogens and Disease

Volumn 72, Issue 1, 2014, Pages 78-86

  Li, Xinyang ^a   Xing, Yingying ^a   Guo, Le ^b   Lv, Xiaobo ^a   Song, Hui ^a   Xi, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Lactococcus lactis; Cholera toxin B; Helicobacter pylori urease; Multi epitope vaccine; Oral delivery

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CHOLERA TOXIN; DRUG CARRIER; EDIBLE VACCINE; EPITOPE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; UREASE;

ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNIZATION; IMMUNOLOGY; LACTOCOCCUS LACTIS; MALE; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PROCEDURES; STOMACH;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL VACCINES; CHOLERA TOXIN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EPITOPES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNIZATION; LACTOCOCCUS LACTIS; MALE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; STOMACH; UREASE; VACCINES, EDIBLE; VACCINES, SYNTHETIC;

EID: 84908213409     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12173     Document Type: Article

References (33)

1. Adams MR & Marteau P (1995) On the safety of lactic acid bacteria from food. Int J Food Microbiol 27: 263-264.
2. Asensi GF, de Sales NFF, Dutra FF etal. (2013) Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model. Microb Cell Fact 12: 32-40.
3. Berlec A, Malovrh T, Zadravec P, Steyer A, Ravnikar M, Sabotic J, Poljsak-Prijatelj M & Strukelj B (2013) Expression of a hepatitis A virus antigen in Lactococcus lactis and Escherichia coli and evaluation of its immunogenicity. Appl Microbiol Biotechnol 97: 4333-4342.
4. Blaser MJ (1990) Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 161: 626-633.
5. Brown LM (2000) Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22: 283-297.
6. Cameron EA & Bell GD (2005) Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther 22: 76-77.
7. Cortes-Perez NG, Kharrat P, Langella P & Bermúdez-Humarán LG (2009) Heterologous production of human papilloma virus type-16L1 protein by a lactic acid bacterium. BMC Res Notes 2: 167-175.
8. Corthesy-Theulaz IE, Hopkins S, Bachmann D et al. (1998) Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoP(c) expressing urease A and B subunits. Infect Immun 66: 581-586.
9. Drouault S, Corthier G, Ehrlich SD & Renault P (1999) Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 65: 4881-4886.
10. Dunn BE, Cohen H & Blaser MJ (1997) Helicobacter pylori. Clin Microbiol Rev 10: 720-741.
11. Ferrero RL, Thiberge JM, Huerre M & Labigne A (1998) Immune responses of specific-pathogen-free mice to chronic Helicobacter pylori (strain SS1) infection. Infect Immun 66: 1349-1355.
12. Fujii R, Morihara F, Oku T, Hifumi E & Uda T (2004) Epitope mapping and features of the epitope for monoclonal antibodies inhibiting enzymatic activity of Helicobacter pylori urease. Biotechnol Bioeng 86: 434-444.
13. Gomez-Duarte OG, Lucas B, Yan ZX et al. (1998) Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 6: 460-471.
14. Gu Q, Song DF & Zhu MY (2009) Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B. FEMS Immunol Med Microbiol 56: 197-203.
15. Guo L, Li XK, Tang F, He YM, Xing YY, Deng XP & Xi T (2012a) Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from Helicobacter pylori urease A subunit. Appl Microbiol Biotechnol 93: 1737-1945.
16. Guo L, Liu KM, Xu GX, Li XK, Tu JJ, Tang F, Xing YY & Xi T (2012b) Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model. Appl Microbiol Biotechnol 95: 1437-1444.
17. Guo L, Yin RT, Liu KM, Lv XB, Li YH, Duan XG, Chu YK, Xi T & Xing YY (2014) Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H.pylori in BALB/c mice model. Appl Microbiol 98: 3495-3507.
18. Hou J, Lu Y, Liu HY etal. (2011) Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice. Vaccine 29: 4102-4109.
19. Huang XY, Xu BL, Duan GC & Song CH (2013) The rOmp22-HpaA fusion protein confers protective immunity against Helicobacter pylori in mice. Curr Microbiol 67: 487-492.
20. Kim SJ, Jun DY, Yang CH & Kim YH (2006) Expression of Helicobacter pylori cag12 gene in Lactococcus lactis MG1363 and its oral administration to induce systemic anti-Cag12 immune response in mice. Appl Microbiol Biotechnol 72: 462-470.
21. Kimoto H, Nomura M, Kobayashi M, Mizumachi K & Okamoto T (2003) Survival of lactococci during passage through mouse digestive tract. Can J Microbiol 49: 707-711.
22. Klijn N, Weerkamp AH & de Vos WM (1995) Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol 61: 2771-2774.
23. Le Loir Y, Nouaille S, Commissaire J, Bretigny L, Gruss A & Langella P (2001) Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis. Appl Environ Microbiol 67: 4119-4127.
24. Le Loir Y, Azevedo V, Oliveira SC et al. (2005) Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb Cell Fact 4: 2-15.
25. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G & Dixon MF (1997) A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112: 1386-1397.
26. McIntyre DA & Harlander SK (1989) Genetic transformation of intact Lactococcus lactis subsp. lactis by high-voltage electroporation. Appl Environ Microbiol 55: 604-610.
27. Sette A & Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461-470.
28. van Asseldonk M, Rutten G, Oteman M, Siezen RJ, de Vos WM & Simons G (1990) Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. Lactis MG1363. Gene 95: 155-161.
29. Van De Guchte M, Jos M, Der Vossen BM, Kok J & Venema G (1989) Construction of a Lactococcal expression vector: expression of hen egg white lysozyme in Lactococcus lactis subsp. lactis. Appl Environ Microbiol 55: 224-228.
30. Wells JM, Robinson K, Chamberlain LM, Schofield KM & Le Page RW (1996) Lactic acid bacteria as vaccine delivery vehicles. Antonie Van Leeuwenhoek 70: 317-330.
31. Zhang HX, Qiu YY, Zhao YH, Liu XT, Liu M & Yu AL (2014) Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant. Mol Cell Probes 28: 25-30.
32. Zhao WF, Wu WT & Xu XD (2007) Oral vaccination with liposome encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H.pylori infection in BALB/c mice. Vaccine 25: 7664-7673.
33. Zhou WY, Shi Y, Wu C, Zhang WJ, Mao XH, Guo G, Li HX & Zou QM (2009) Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 27: 5013-5019.